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Malignant  cells can be destroyed  in  vitro by different  cell types of the immune 
system (1-4).  If lymphoid cells have important surveillance functions  in restraining 
malignant  growth  in  vivo, malignant  cells must circumvent  immunity before pro- 
gressive growth  can  occur.  Neoplasms frequently  develop as  a  clone  from a  single 
transformed cell (5, 6), and during clonal evolution, phenotypic variants commonly 
arise, apparently as a  result of the genetic instability that malignant cells acquire as 
a  consequence of malignant transformation  (6).  If these phenotypic variants have a 
selective  growth  advantage  and  can  escape  immunological  or  other  homeostatic 
control  mechanisms of the  host,  they become the  precursors  of a  newly  emerging 
subpopulation  that  then  becomes  dominant.  Therefore,  these  phenotypic  changes 
indicate  which  kind  of selection  pressures  have occurred  (6),  and  a  study of these 
"fingerprints" should give insight  into the relative importance and hierarchy of the 
different naturally occurring immune defense mechanisms. 
Fibrosarcomas that have been induced experimentally in C3H mice by ultraviolet 
radiation  (UV) 1 seem ideal  for studying the selection of progressor variants by the 
normal  host.  Most  of these  fibrosarcomas will  not  grow progressively when  trans- 
planted  into normal young syngeneic C3H mice and are termed regressor fibrosar- 
comas  (7);  however,  the  tumor will  grow  progressively when  transplanted  into  x- 
irradiated  thymectomized, nude  (7), or old animals (8, 9). Therefore, these fibrosar- 
comas consist  of potentially malignant  cells that  can be used  to study the  relative 
importance of different immune surveillance mechanisms that may function in normal 
immunocompetent animals. 
In this paper, we demonstrate that tumor variants can arise spontaneously from a 
regressor fibrosarcoma and can be selected for by normal nonimmunized hosts; these 
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variants  are  termed  progressor  fibrosarcomas.  We  describe  several  progressively 
growing variants of the UV-induced  1591  regressor fibrosarcoma and report studies 
on changes in susceptibility of the variants to natural killer cells and to tumor-specific 
or  cross-reactive  T  cell-mediated  immunity.  These  progressor  variants  lose  their 
original tumor-specific transplantation antigen in a heritably stable fashion but retain 
their  sensitivity to  natural  killer  (NK)  cells and  to  cross-reactive T  cell-mediated 
killing. In fact, the variants seem to induce cross-reactive T  cells more efficiently than 
the parent regressor tumor, and the variant tumor cells are more sensitive to lysis by 
NK cells even though these tumors grow progressively. This suggests that, at least in 
this tumor system, the ability of normal immunocompetent  animals to reject poten- 
tially tumorigenic cells depends absolutely on  the  presence of an  immune  response 
against  tumor-specific transplantation  antigens  and  not  upon  the  presence  of NK 
activity and/or cross-reactive T  cell-mediated immunity in vivo. 
Materials and  Methods 
Mice.  5- to  10-wk-old female C3H/HeN  (mammary  tumor virus-negative) mice from  a 
colony of germ-free-derived, specific pathogen-free animals were purchased from the Frederick 
Cancer Research Center Animal Production Area. They were kept at the La Rabida Institute 
in laminar flow hoods and were given sterilized food (Purina 5010C for autoclaving) and water. 
The original stock of nude C3H/HeN mice were in the 23rd backcross generation when they 
were obtained from a colony at the Biology Division of the Oak Ridge National Laboratory. 
Fibrosarcoma Lines.  The fibrosarcomas 1591,  1316, 1463, and 2240 were induced in C3H/ 
HeN mammary tumor virus-negative (MTV-)  mice (7). These fibrosarcomas have noncross- 
reacting tumor-specific transplantation antigens (10). Tumors  1591,  1316, 1463, and 2240 are 
strongly immunogenic, i.e., these tumors, when transplanted into young syngeneic mice, grow 
during the first 10 d and then regress. These tumors can grow progressively, however, in nude 
mice or in syngeneic mice that are immunosuppressed by either UV irradiation or by adult 
thymectomy  and  x-irradiation  (7),  eventually  killing these  animals  by  infiltrative growth 
without macroscopic evidence of distant metastases. 
Tumors were adapted to growth in vitro by mincing ~ 1 cm  3 of viable tumor into fragments 
and seeding the fine suspension into a  75-cm  * tissue culture flask. Nonadherent particles were 
removed after 3 h, and the cells were immediately grown up  to mass culture and frozen in 
aliquots for later use. The 1591,  1316, and 2240 cell lines were then cloned by diluting out the 
cells in Terasaki tissue culture plates (3034;  Falcon Labware, Div. of Becton, Dickinson & Co., 
Oxnard, Calif.). 24 h  later, each well was examined microscopically for cell attachment, and 
wells that contained a single attached cell were chosen for clonal amplification. This procedure 
was repeated once to ensure the clonal nature of each cell line. 
Normal  fibroblast lines were derived from  heart  and  lung tissue obtained from an  adult 
C3H/HeN  (MTV-)  mouse  (referred  to  as  HLF).  These  fibroblast lines are  not  killed by 
activated macrophages and do not form tumors when as many as 1 ×  107 cells are injected into 
a  syngeneic nude mouse (3-mo observation period). All fibroblast cell lines were cultured in 
minimal essential medium, containing 10% heat-inactived fetal bovine serum and 1% penicillin- 
streptomycin (CMEM). YAC (Moloney virus-induced lymphoma) cells were cultured in RPMI 
supplemented as described by Burton and Winn (11).  All cell lines used in these experiments 
were routinely examined for the possibility of mycoplasma contamination using culture and 
DNA staining techniques. 
The  results  obtained  by  other  investigators  with  vitally-induced tumor  cell  lines  have 
indicated that the sensitivity to lysis by NK cells may increase after about 3 wk of culturing 
(12,  13). We, therefore, only used the progressor cell lines in the first 2 wk after explantation 
from the host. Furthermore, the low NK sensitivity of the parental 1591 regressor cell line has 
not increased with prolonged passage in vitro (observation period >2 too), in agreement with 
the results of others  (14,  15)  that  NK sensitivity can be a  stable characteristic of cell lines. 
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within 2 wk of explantation were cryopreserved in aliquots (16). When these cells were used as 
stimulator cells in a mixed lymphocyte-tumor cell culture (MLTC), as targets in a chromium- 
51  (SlCr)-release  assay, or for in vivo challenge, an aliquot was thawed and used within 24 h. 
Batches of various types of effector  cells were also cryopreserved for use as internal controls in 
present and future experiments. 
MLTC.  Culture medium was RPMI  1640 medium supplemented with  10% fetal bovine 
serum,  1%  penicillin-streptomycin,  and 5  ×  10  -5 M  2-mereaptoethanol added immediately 
before use.  Spleens were removed aseptically from animals that had received either bilateral 
subcutaneous implants of l-mm  3 tumor fragments in the inguinal fossae or an intraperitoneal 
injection of 1 ×  107 cultured tumor cells. Spleens were made into single cell suspensions using 
a ground glass homogenizer. The cells were then washed with complete culture medium, treated 
once with 0.83% (wt/vol) ammonium  chloride to lyse erythrocytes, and then washed once again 
with culture medium. Tumor cells used as stimulators were treated with 50 #g/ml mitomycin 
C (Sigma Chemical Co., St. Louis, Mo.)  for 45 min at 37°C and then washed three times with 
culture medium. MLTC for the generation of tumor-specific cytolytic T  cells were made by 
adding 2.5 ×  107 responder lymphocytes and 2.5 ×  105 mitomycin C-treated stimulator cells in 
20  ml  medium in a  25-em  2 tissue culture flask  (3013;  Falcon Labware).  The  flasks  were 
incubated upright at 37°C in a fully humidified 5% CO2 atmosphere for 6 d. 
Generation ofCytotoxic Lymphocytes In Vivo.  Cytolytic peritoneal lymphocytes were induced by 
a  modification of a  method  described  by  Newcomb  et  al.  (17). Mice  were  injected once 
intraperitoneally with  1  ×  107  mitomycin C-treated  or  untreated cultured tumor cells  in 
phosphate-buffered  saline.  At  various  times  thereafter,  the  mice  were  killed  by  cervical 
dislocation, and their peritoneal cavities were rinsed with 5 ml of CMEM containing 5 U/ml 
heparin. The peritoneal cells were washed with CMEM and then incubated in 96-well  tissue 
culture plates (Linbro Chemical Co., McLean, Va.), with  1 ×  106 to 3 ×  106 cells in 200 7~ 
CMEM per well for 1 h at 37°C. Cells not adhering to the plastic were washed and used as 
effectors for 6-h or 16-h chromium release assays. 
Chromium Release Assay.  Target cells (1 ×  106 to 2 ×  10  e') were labeled with 100 btCi 51Cr for 
1 h at 37°C. Each batch of effector cells in a volume of 100 ~ was serially diluted in V-bottomed 
96-well microtiter plates (Cooke,  Alexandria, Va.) and mixed with 5 ×  103 to  10 ×  103 51Cr- 
labeled cells in 100 ~ CMEM. After 1, 6, or 16 h of incubation  as specified,  100 ~ of supernatant 
medium was withdrawn and assessed  for  radioactivity using a  gamma counter. The SD of 
replicate samples was 5-10% of the mean. The percentage of specific lysis was calculated by the 
formula: 
experimental release -  spontaneous release 
percent specific lysis ----  total release -- spontaneous release  ×  100 
Spontaneous release  was <15% of the maximum release  of radiolabel during the 1-h and 6-h 
incubation periods and <25% of the maximum release during the 16 h incubation period. The 
hypotonic release was 80% of the incorporated counts for all target cells. 
In some  experiments, effector  cells  were  depleted  of Lyt-2  +  cells  by  incubation with  a 
monoclonal anti-Lyt-2 hybridoma antibody for 30 min at 4°C, followed  by incubation with 
rabbit complement for 45 min at 37°C. A  1:2 dilution of culture supernatant from the anti- 
Lyt-2 IgM hybridoma 2.155.2  (18) was used and was a generous gift of Dr. F. W. Fitch of the 
University  of Chicago, Chicago, Ill. Control effectors were treated with medium instead of anti- 
Lyt-2 supernatant followed  by rabbit complement. Rabbit complement used in these experi- 
ments was serum from selected  animals with low natural cytotoxicity to mouse spleen cells. 
This complement was subsequently absorbed with 80 mg of agar per ml of serum and used at 
a final concentration of 1:12. Using the same general procedures, effector cells were depleted in 
some experiments of NK1.2  + or Thyl.2  ÷ cells using a  1:50 dilution of an anti-NK-1.2 serum 
(CE  ×  NZB-Fx  anti-CBA)  (11) or  a  1:50 dilution of an anti-Thy-l.2 hybridoma antibody 
(AT83AB), obtained from Dr. F. W. Fitch of The University of Chicago. 
Results 
Derivation  of Progressor Variants.  The  1591  tumor rarely grows progressively when 
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mice;  for example, after two passages of the  tumor in  x-irradiated  thymectomized 
mice, two  1-mm  3 fragments of the  1591 tumor were implanted into each of 300 8- to 
10-wk-old mice, and only one of the animals developed a progressively growing tumor. 
We anticipated that the chance of obtaining variants that can grow progressively in 
normal mice might be increased if the tumor was serially passed in immunosuppressed 
mice because  the  likelihood  of generating  a  progressor variant  should  be a  direct 
function of the number of generations of tumor cells (6).  Therefore, we passaged the 
tumor serially in aduh-thymectomized, sublethally-irradiated (450 rad) mice that will 
accept the  1591 tumor (75-85% of the recipients develop 1-cm tumors within 6 wk). 
After five such passages, a tumor inoculum consisting of five l-ram  a fragments of the 
tumor was implanted subcutaneously into the inguinal region of 100 3-mo-old normal 
mice.  Progressively growing tumors were observed in  five of these animals  1-4 mo 
after implantation. These tumors were isolated when they had grown to a size of 1.5- 
2.5 cm in diameter and coded as 1591 progressor-1 to 1591 progressor-5. Tissue culture 
cell lines were immediately established for each of these tumors and expanded  into 
large batches in <2 wk for cryopreservation. Fragments dissected from each of these 
tumors, when reinjected as single  1-mm  a fragments subcutaneously into -->20 normal 
mice, produced progressively growing tumors in >80% of the animals, thus demon- 
strating the heritable nature of the progressive growth behavior of each of the five 
newly isolated tumors. Furthermore, fragments from tumors developing in nude mice 
receiving an  injection  of progressor tumor cells  from the  established  tissue  culture 
lines also showed a  tumor incidence of ~80%. The tumor incidence  in normal mice 
did  not  decrease  when  tumor fragments obtained  after two  additional  passages in 
nude mice were used;  the same was true for fragments obtained from tumors arising 
in nude mice injected with tumor cells from the established tissue culture cell lines. 
Secondary Response of Spleen Cells  from Animals in Which the Progressor Tumors Arose.  We 
have  previously  demonstrated  (19)  that  the  presence  of  1591-specific  lymphocyte 
clones  is necessary for animals to resist  a  challenge with this  tumor. Therefore, we 
tested whether or not the five 1591-injected animals in which the progressor tumors 
developed possessed specific immunity to the parental  1591 tumor. Spleen cells from 
each  of these  animals  were  tested  in  individual  experiments  for  specific  cytolytic 
activity after a 6-d stimulation with parental  1591 cells in a mixed lymphocyte tumor 
cell culture. In each of these experiments, at least one control animal that had rejected 
the  1591 tumor was tested concurrently in the same assay. The results of the assays 
with  lymphocytes obtained  from the different  tumor-bearing animals were similar; 
therefore, the results were pooled. Similarly, the results for the controls were similar 
and  were  pooled.  Fig.  1 A  shows  that  spleen  cells  from  tumor-bearing  animals 
developed  significant  cytolytic  activity  towards  the  parental  1591  tumor cells,  al- 
though it appeared to be somewhat less than in control animals that had rejected the 
tumor  (Fig.  1 B).  The  most striking  difference between  tumor-bearing and  control 
animals was the high degree of cross-reactivity observed in the cultured  spleen cells 
from  the  five  tumor-bearers.  This  reactivity  did  not  appear  to  be  selective  for 
malignant  targets  because  nontumorigenic  syngeneic  HLF  were  also  lysed  to  a 
significant degree. 
Secondary Immune Response of Spleen Cells to Transplanted Progressor Tumors.  The above 
results show that lymphocytes from normal animals in which the progressor tumors 
developed exhibited cross-reactive cytotoxic activity in culture. However, the kinetics URBAN  ET  AL.  561 
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Flo.  1.  Cross-reactive cytolytic immunity of animals that developed progressively growing tumors 
after implantation of fragments of the parental 1591 tumor (A) and specific cytolytic immunity of 
animals that had rejected the parental 1591 tumor (B). Spleen cells were removed  1-4 mo after 
tumor challenge, restimulated  with the parental 1591 tissue culture cell line for 6 d in a mixed 
lymphocyte tumor cell culture, and then used as effectors in a 6-h SlCr release assay. Five animals 
that developed progressively growing tumors were individually analyzed and compared with seven 
concurrent control animals that had rejected the tumor fragments in five independent experiments. 
The results of these experiments were similar and therefore pooled. Vertical bars indicate the SE of 
the results for individual animals. (A) Progressor spleen cells, and (B) regressor spleen cells. Target 
cells are indicated as follows: H,  1591 regressor (parental);  A  A, 2240; O  O,  1316; 
•  A, HLF. 
of development, antigen dependence,  and phenotype of the cross-reactive cells gen- 
erated in vitro had not been studied. Thus,  nude and normal animals were injected 
with either progressor or parental tumor cells. At various times thereafter, spleen cells 
were removed and restimulated in a  6-d MLTC  and then tested for cytolytic activity 
in a  6-h chromium  release assay. Fig. 2  shows that  injection of progressor cells into 
normal animals induced a significant cytolytic response directed against the progressor 
targets, which peaked 20-30 d  after tumor challenge. The lymphocyte response was 
totally cross-reactive with the unrelated UV-induced fibrosarcoma 2240.  In contrast, 
normal animals injected with the regressor tumor cells exhibited a  response that was 
specifically  directed  against  the  parental  regressor  tumor.  This  specific  response 
peaked earlier than the cross-reactive response elicited in pro~gressor-injected animals 
and  was  greater  in  magnitude  (note  difference in  effector-to-target ratio  (E:T)  for 
regressor-injected vs.  progressor-injected animals).  Under  the same conditions, lym- 
phocytes  from  nude  mice  injected  with  progressor cells did  not  exhibit  significant 
cytolytic activity. For normal  animals  immunized  with  progressor tumor cells, one 
animal at each time point had been injected with a nontumorigenic dose (1  ×  107) of 
tissue culture cells, and therefore a direct comparison could be made between animals 
with  and  without  progressively  growing  tumors.  However,  no  difference  in  the 
magnitude  of cross-reactive cell-mediated immunity  could  be  observed,  indicating 
that reactivity was not influenced by the presence of a  tumor mass. 562  MECHANISMS  OF SYNGENEIC TUMOR REJECTION 
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F=o. 2.  Kinetics  and specificity of cell-mediated immune reactivity generated by normal but not 
by nude animals in response to previous in vivo challenge with progressor or regressor tumor cells. 
Spleen cells were removed at various times after tumor challenge, restimulated in vitro with the 
same tumor for 6 d, and then tested for cytolytic activity against target cells 2240, 1591 progressor 
(1591 PRO),  or 1591 regressor (1591 RE) in a 6-h ~lCr release assay. The number  of animals 
analyzed at each time point is given in parentheses, and the vertical bars indicate the SE of their 
individual analysis. Differences in E:T are indicated in the figure. 
We  analyzed  further  the  reactivity  pattern  of cultured  cytolytic  lymphocytes 
obtained from normal animals injected with either progressor or regressor tumor cells 
and  tested  for reactivity against  a  variety of target  cell  lines  near  the  time of peak 
response (30 d post-injection). Fig. 3 shows that animals injected with progressor cells 
generated  tumor-reactive  lymphocytes  that  lysed  equally  well  two  unrelated  UV- 
induced fibrosarcomas and the nontransformed syngeneic HLF. Lymphocytes gener- 
ated in animals injected with regressor cells exhibited selective cytolytic activity. Thus 
the  pattern  of cross-reactive  cytolytic  activity  demonstrated  by  culture-generated 
spleen cells from progressor-injected animals was similar to t~aat of spleen cells from 
the animals in which the progressor tumors developed. Furthermore, progressor tumor 
cells when used as targets were as resistant  as other unrelated  target cell lines to the 
effects of the in vitro-generated  1591-specific T cells. This suggested that the progressor 
variants  had  lost  the  original  tumor-specific  antigen,  and  this  antigenic  change 
remained  heritably stable over 3 mo of continuous passage of the cell lines.  Table I 
shows that  the cross-reactive cytolytic activity generated  in cultures  of lymphocytes 
from progressor-injected  animals  was  dependent  on  previous  injection  of tl~e  mice 
with  progressor cells  but  did  not  require  antigen-specific  restimulation  in  vitro.  In 
contrast,  the  generation  of  1591-specific  T  cells  depended  on  the  presence  of the 
specific antigen in the mixed lymphocyte-tumor cell culture. URBAN  ET  AL.  563 
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Fie.  3.  Cross-reactive cytolytic immunity of animals injected with progressor tumor cells (A) and 
specific  cytolytic  immunity  of animals  injected  with  regressor  tumor  cells  (B).  Spleen  cells  were 
removed 20-40 d after tumor challenge, restimulated  for 6 d  in culture with the same cell line used 
for in vivo injection,  and then used as effectors in a 6-h SlCr release assay.  13 animals injected with 
progressor tumor ceils and 11 animals injected with regressor tumor cells were individually analyzed 
in nine separate experiments, and a total of five progressor cell lines were separately tested in these 
experiments.  The  results  of these  experiments  were  similar  and  therefore  pooled.  Vertical  bars 
indicate  the  SE  of  the  results  for  individual  animals.  Target  cells  are  indicated  as  follows: 
H,  1591  regressor (parental); []  r-l,  159t  progressors  (variants); A  A, 2240;  O  C), 
1316; •  •,  HLF. 
TABLE  I 
Lack of Specific Immunologic Memory of Animals Injected with Progressor Cells and Failure of Progressor 
Cells to Restimulate a Specific Memory Response to the Parental Regressor Cells 
Number of  Stimulator 
Animal  animals  Pretreatment of host*  cells in 
analyzed  MLTC 
Percent specific  lysis of target cells~: 
100:1  25:1 
Regressor  Progressor  2240  Regressor  Progressor  2240 
Normal  8  Regressor-injected  Regressor  99 ±  6§  26 ±  9  29 ±  4  90:1= 7  9 ±  3  9 =t: 4 
Progressor  20 +  2  43 "# 7  31 +  5  12 +  3  9 ±  2  8 ~  2 
None  22±3  27±10  36±7  10+3  9±4  7±3 
18  Progressor-injected  Regressor  58 :l: 8  55 ±  7  74 ±  9  25 ±  7  22 ±  5  24 +  5 
Progressor  56 +  5  70 ±  5  84 ±  6  18:1:5  22 ±  4  27 ±  4 
None  42±5  53±7  73+8  9±3  17±4  15:1:5 
5  None  Regressor  6 ±  3  6 ±  4  4 ±  4  2 ±  1  4 ±  3  1 ±  3 
Progressor  25+4  23±11  17±2  3±2  3±2  2±2 
None  10±3  18±1  15"+'7  3±2  -1±3  -I±3 
Nude  7  Progre"~or-injected  Regressor  11 ±  3  6 ±  5  10 ±  5  3 ±  4  3 ±  3  0 ±  3 
Progressor  2:1:1  5±7  --1"+3  --1-+'3  --4±2  0±3 
None  0±2  5±8  --2 :t: 4  --l±1  0±4  0±3 
* Normal or nude C3H mice were injected subcutaneously either with the parental  regressor  1591  or with one of the five  i591 progreasor 
variants. Spleen cells  from  these animals were removed 20-30 d later and restimulated in a 6-d MLTC with the regressor  or corresponding 
progressor  tumor cells or with the medium alone. 
¢ Effector cells generated in MLTC were tested in a 6-h SlCr release assay using regressor,  progressor,  or 2240 tumor cells as targets at a  100: I 
or 25:1  E:T. Percent specific  lysls was calculated as described in Materials and Methods. 
§ Values represent the mean -l.- SE for the individual analysis of the number of animals indicated. The data are pooled  from  eight separate 
experiments and the responses  to all five progressor  variants were analyzed. 564  MECHANISMS  OF SYNGENEIC TUMOR  REJECTION 
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FIo. 4.  Characterization of specific effector cells from animals injected with regressor tumor cells 
(A) and of nonspecific  cells from animals injected with progressor tumor cells (B). Spleen cells were 
removed 35 d after challenge with the 1591 tumor, restimulated for 6 d in culture with 1591 tumor 
cells, and then used as effector cells in a 6-h 51Cr-release assay using 1591 tumor cells as targets. 
Before the  51Cr-release assay, effector cells were treated  with  anti-Lyt-2  or  anti-Thy-l.2  and 
complement or with  complement  alone, as  described in  Materials and  Methods. The  target 
specificity of such effector cells is shown in Fig. 3. H  rabbit complement alone; •  •, ot- 
Lyt-2 + rabbit complement; O- - -©, a-Thy-l.2 + rabbit complement. 
The tumor-specific cytolytic activity of  culture-generated lymphocytes from animals 
injected  with  the  parental  tumor  was  eliminated  effectively by pretreatment  with 
anti-Thy-l.2 or anti-Lyt-2 antibody and complement (Fig. 4). In contrast, the much 
lower cytolytic activity of the cross-reactive lymphoid cells  from progressor-injected 
animals  (note differences  in E:T) was diminished  by <60% after pretreatment  with 
anti-Thy-1.2 and complement and only by -40% after pretreatment  with anti-Lyt-2 
and  complement.  This  was  markedly  less  than  the  >90%  reduction  of the  tumor- 
specific cytolytic activity  after  anti-Lyt-2 pretreatment  of the  antigen-specific  lym- 
phocytes  obtained  from  regressor-injected  animals.  Pretreatment  of the  immune 
spleen cells from progressor-injected  mice with anti-NK antiserum  and complement 
at the beginning of the 6-d culture period did not affect the degree of cross-reactivity 
generated  by these cells,  whereas  pretreatment  with  anti-Thy-l.2  and complement 
virtually abolished the generation of this reactivity (data not shown), indicating that 
cross-reactivity could not be attributed  to NK cells. 
Primary Immune Response of  Peritoneal Lymphocytes to Transplanted  Progressor Tumors.  The 
results of the above in vitro experiments suggested that animals bearing progressively 
growing tumors may be incapable of generating tumor-specific~ymphocytes and that 
all of the five different  progressor tumor cell  lines were resistant  to the effects of in 
vitro generated  tumor-specific cytolytic T  cells.  To confirm the significance of these 
results  in vivo, we challenged normal animals intraperitoneally  with either parental 
1591 or progressor 1591  tumor cells. 8 d  thereafter,  nonadherent peritoneal cells were 
studied  for their  cytolytic activity towards  parental  or progressor  1591  tumor cells 
and towards control tumor cells derived from the unrelated UV-induced fibrosarcoma 
1316.  Figure  5A  shows  that  only  animals  challenged  with  the  parental  tumor 
generated  cytolytic activity  that  was  tumor-specific;  furthermore,  cytotoxicity was 
totally eliminated  by pretreatment  of the effector cells with anti-Lyt-2 and comple- 
ment.  Interestingly, animals challenged with progressor tumor cells also generated a URBAN ET AL.  565 
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FIo. 5.  (A) Induction of  cross-reactive cytolytic immunity by intraperitoneal injection ofprogressor 
tumor cells from the five different progressor tumors 8 d previously and induction of tumor-specific 
cytolytic immunity by a similar  injection of regressor tumor cells into normal C3H  mice. The 
vertical bars indicate the percent lysis of target cells (RE, regressor 1591 parental tumor cells; PRO, 
progressor 1591 variant tumor cells; 1316 tumor cells) in a 6-h 51C~r release assay after treatment of 
the effector cells with anti-Lyt-2 and complement  ([]) or after treatment with complement alone 
~). Progressor targets are totally insensitive to Lyt-2  + regressor-specific  T cells, and regressor targets 
are less sensitive than progressor targets to Lyt-2- lymphocytes. Vertical lines show the SE of values 
obtained from  individual analysis of animals  injected  with  regressor tumor cells (11  animals), 
progressor tumor cells (eight animals), or noninjected  (five animals), obtained in four independent 
experiments.  E:T, 200:1. (B) Induction of cross-reactive cytolytic immunity by injection of either 
progressor or regressor tumor cells into nude C:3H mice, individually tested in three independent 
experiments (one animal per injection per experiment). For other details see part A. 
significant level of cytolytic activity. These  lymphocytes, however, were completely 
insensitive to treatment  with  anti-Lyt-2 and  complement  and  lacked the exquisite 
specificity observed  with  lymphocytes  from  animals  immunized  with  the  parental 
1591  tumor.  Finally, in agreement  with our earlier in vitro findings, it can  be seen 
from Fig. 5 A that the progressor tumor cells were not sensitive to lymphocytes specific 
for the parent  1591  tumor,  indicating again that  the progressor tumor cells lost the 
original 1591  tumor-specific antigen. Fig. 5 B shows that nude mice were also capable 
of  generating  significant  cytolytic  activity;  however,  this  activity  was  relatively 
insensitive to anti-Lyt-2 and complement  treatment  regardless of whether  the nude 
mouse had been injected with regressor or progressor cells. Thus, this cytolytic activity 
resembled that of normal mice injected with progressor cells. 
To test whether the progressor-reactive cells generated by nude and normal mice 
were  related to  NK  cells, we tested  their ability to kill YAC  target  cells and  their 
expression of the NK1.2 surface marker. In a chromium release assay, these progressor- 
induced,  progressor-reactive lymphocytes lysed not  only the progressor target  cells, 
but  also YAC  target  cells (Table  II).  This  activity was  almost  totally removed  by 566  MECHANISMS OF SYNGENEIC TUMOR  REJECTION 
TABLE  II 
Differentiation  Markers on NK Lymphocytes and Increase of NK Activity after Injection of the Host with 
Progressor Tumor Cells 
Pretreatment of  Source of effector  Pretreatment of 
host*  cells  effector cells$ 
Percent specific lysis of target 
cells§ 
Progressor ceils  YAC cells 
6h  16h  6h  16h 
Noninjected  Peritoneal cavity  C' alone  10  17  38  53 
C' +  anti-Lyt-2  10  19  30  62 
C' +  anti-NK-1.2  2  11  <0  <0 
Spleen  C' alone  10  15  66  74 
C' +  anti-Lyt-2  11  16  66  81 
C' +  anti-NK-1.2  7  2  6  7 
Progressor-injected  Peritoneal cavity  C' alone  45  83  85  94 
C' + anti-Lyt-2  37  82  81  90 
C' +  anti-NK-1.2  7  20  28  17 
Spleen  C' alone  20  56  93  100 
C' + anti-Lyt-2  19  51  87  86 
C' + anti-NK-1.2  6  16  15  21 
* C3H mice were injected with 107 live progressor  1591 tumor cells intraperitoneally. Spleen or peritoneal 
exudate cells were removed and tested 8 d after injection. 
$ Effeetor cells were depleted of adherent cells and then treated with antisera and/or complement before 
testing in a SaCr-release assay as described  in Materials and Methods. 
§ Effector cells were tested in a 6-h and  16-h SaCr-release assay using as target cells progressor  1591 or YAC 
tumor cells at a 200:1 E:T. Percent  lysis was calculated as described  in Materials and Methods. 
pretreatment  with  anti-NK-1.2  antibody  and  complement.  In  the same experiment, 
this reduction  in activity was demonstrated  to be equivalent to a  >95%  reduction  in 
the number  of effector cells (data not shown).  As shown above, the effector cells were 
insensitive to  anti-Lyt-2  and  complement  treatment.  The  results  were  similar when 
splenic rather  than  peritoneal lymphocytes were used as effectors. 
The  results we have presented  show that,  in normal  mice, progressor  variants  can 
induce natural  killer activity much more effectively than the parental  regressor tumor 
(Fig. 5 A), whereas in the nude mouse, the parental  tumor could induce natural  killer 
activity  equally  effectively  (Fig.  5B).  Furthermore,  the  parental  tumor  cells  were 
consistently  less sensitive than  the progressor variants  to the NK  cells. This relatively 
lower NK sensitivity of the parental tumor cells has not increased even with prolonged 
passage  in  vitro for many  months.  Furthermore,  the  higher sensitivity of progressor 
variants  and  their  increased  capacity  to  induce  NK  activity  in  normal  mice  was 
apparent  even  in  primary  progressor  cell  cultures  and  has  not  changed  thereafter 
(data not shown). 
Growth  Kinetics  of  Progressor  Tumors  in  Normal  and  Nude  Mice.  Because  in  our 
experience C3H  nude  mice demonstrate  the same NK  activity as normal  C3H  mice, 
we expected that  the progressor variants would grow in nude and  normal animals at 
the same rate. To test this hypothesis, nude and normal animals were injected with  l- 
mm 3 fragments  of the  progressor  tumors  and  then  monitored  for  differences  in  the 
rate of tumor appearance.  Interestingly, several differences in the growth behavior of 
the progressor tumors were found between normal and nude hosts. 
First, as shown in Fig. 6, tumors  appeared  earlier in nude mice, although  >80% of IOC 
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FIG. 6.  Rate of tumor appearance in nude (O"-------~)  and normal (O  O) C3H mice injected 
with the progressor variants  (two 1-mm  3 fragments per mouse). The results of three independent 
experiments, each of which tested a different PRO line in two and four normal animals, were similar 
and therefore pooled. Animals were scored as positive for tumor growth when tumors reached 0.4- 
cm Diam and continued to progress to eventually kill the animals. 
normal as well as nude animals eventually developed progressively growing tumors. 
At  day  12  post-injection, all nude  mice had  developed tumors,  whereas  no  tumors 
were  yet  observed  in  normal  animals.  The  average  time  interval  after  which  the 
progressor tumors became macroscopically visible in nude mice was 9.0 d  (zl: 2.7, SD), 
whereas the average time interval for tumor appearance in normal mice was 21.0  d 
(+ 7.4 d, SD; P<  0.01). 
Second, tumors in nude mice reached an average diameter of 1-cm as early as  12 
d  after implantation, whereas tumors transplanted in normal mice did not reach this 
average size until 36 d  after transplantation. A  third characteristic difference between 
the progressor tumors growing in normal and nude mice was the conspicuous absence 
of macroscopic central necrosis in even 3-era diam tumors growing in nude mice as 
compared to the regular presence of marked central necrosis in tumors exceeding even 
1-cm Diam in normal mice. 
Lineage Relationship of the Progressor Tumors.  The lineage relationship of the progres- 
sor  variants  was  tested  by  determining whether  the  progressively growing  tumors 
exhibited a  surface  marker  that  is restricted to  a  small percentage  of UV-induced 
fibrosarcomas, including tumor  1591.  This marker was  defined by reactivity with a 
hybridoma antibody (P67)  obtained from a  fusion of mouse P3  myeloma cells with 
spleen cells from a  1591  tumor cell-immunized rat.  Of 10 syngeneic fibroblast lines 
tested,  only  the  1591  and  the  1463  regressor  fibrosarcomas selectively express  this 
marker,  either  measured  by susceptibility of the  fibrosarcoma cells to  lysis by  the 
hybridoma  antibody  and  complement  or  measured  by  cytofluorometry  analysis. 
When the expression of the P67 marker was tested on the five 1591  progressor tumor 
lines, four of the five expressed the marker, and this expression was stably heritable as 
determined by three repeated analyses several weeks apart. The retention of at least 
some level of expression of the P67 marker in four of five progressor tumors suggested 
a  lineage relationship with the parental  1591  tumor.  Furthermore, there were differ- 
ences in the level of P67 expression that suggested that the different progressor tumors 
were not identical. The results of these studies will be published separately.  2 
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Discussion 
Our  studies  show  that  during  the  growth  of the  1591 tumor,  heritably  stable 
variants arose that could neither be killed by 1591-specific T  cells nor stimulate the 
generation  of such  1591-specific effector cells in  vivo or in  vitro.  The generation of 
heritably stable tumor cell variants is thought to be a direct function of the number 
of generations of tumor cells  (6).  Consistent with this notion  is the fact that several 
repeated passages in  immunosuppressed hosts were required  to allow for the devel- 
opment of a significant number of tumor variants before they could be selected for in 
normal  animals.  Presumably,  the  1591 parental  tumor was  of unicellular  (clonal) 
origin. This is suggested by the fact that UV-induced cancers originate as single loci 
in the relatively large area of UV-exposed skin. Nevertheless, more than one cell may 
have been simultaneously affected (transformed) by the carcinogen, and multicellular 
transformation  appears to  be  a  frequent  occurrence  for fibrosarcomas induced  by 
subcutaneous injection of methylcholanthrene  (20).  In any case, passage of the  1591 
tumor in  immunosuppressed and then  normal mice led  to the emergence of tumor 
cells that were phenotypically different  from the previously dominant  phenotype of 
the parental tumor cell population. 
Whenever  phenotypic  changes  are  found  to  occur  in  tumor  populations,  the 
possibility of laboratory contamination needs to be excluded. Several lines of evidence 
strongly argue against such a  possibility. First,  the P67  marker, whose expression is 
restricted to few UV fibrosarcomas, was retained by four of the five isolated progressor 
tumors.  Second,  there  were  significant  differences  among  the  progressors  in  cell 
morphology,  growth  behavior  in  vitro,  and  expression  of the  P67  marker.  These 
findings make it highly unlikely that all the variant tumors could have derived from 
a single laboratory contamination. Thirdly, we have recently discovered (unpublished 
results)  that  the  twice-cloned  parental  1591 fibrosarcoma  cell  line  is  capable  of 
spontaneously  generating  similar  heritable  variants  in  vitro,  including  those  that 
differ  in  expression  of the  tumor-associated  P67  marker  and  in  expression  of the 
tumor-specific transplantation antigen. Thus, at least in culture, a single clone of 1591 
cells is capable of generating variants differing in expression of the tumor-associated 
marker,  and  a  muhicellular  origin  of the  tumor  is  not  necessary  to  explain  the 
differences observed in the  1591 progressor tumors isolated from the animals. 
The  argument  can  be  raised  that  the  loss  of  the  tumor-specific  antigen  was 
incidental and not related to selection by a tumor-specific immunologic host defense 
mechanism.  Several  lines  of evidence  make  this  highly  unlikely.  First,  all  of the 
progressor tumors we independently  isolated showed a  complete loss of the tumor- 
specific transplantation antigen, Second, we have previously shown (19) that the 1591 
antigen is never lost from 1591 tumors growing in hosts whose 1591-specific immunity 
had been selectively suppressed with anti-idiotypic immunity. These animals retained 
their normal resistance to other UV-induced fibrosarcomas. Third, in vitro exposure 
of the parental  1591 tumor to a  1591-specific cytolytic T  cell line is sufficient for the 
selection of variant tumor cell lines that have lost the expression of the original  1591- 
specific antigen (Richard Wortzel et al., manuscript in preparation). Thus, we propose 
from the above (a)  that the outgrowth of tumorigenic variant cells, all of which lost 
the original  1591-specific antigen, was due to a resistance to the selection pressures of 
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malignant  parental  1591 cells  depended  upon  the  expression  of the  1591-specific 
antigen. 
Collins et al.  (15)  report that the tumorigenicity of fibroblast cell lines chemically 
transformed in  vitro correlated  inversely with sensitivity to NK cells.  However, no 
selection  for  progressor  variants  from  the  nontumorigenic  NK-sensitive  cells  was 
performed. Such studies would determine whether sensitivity to NK cells was lost by 
progressor variants and would indicate whether a causative link between progressive 
growth and the loss of sensitivity to NK effector cells exists. In contrast, we have used 
cells  transformed  in  vivo  to  study  how  NK-sensitivity  changes  when  progressor 
variants arise in normal animals. Interestingly, we found that no selection against NK 
activity occurred during the evolution of progressor variants from the parental  1591 
tumor.  In fact, tumor cells of the different  progressor cell variants induced  natural 
killer activity more effectively than the parental tumor cells.  These natural killer cells 
exhibited  the classical  reactivity and surface differentiation  markers previously de- 
scribed to be present on natural killer cells (11). 
At present we do not know whether the increased capacity of our progressor variants 
to  induce  and  to be killed  by natural  killer  cells  is  an  obligatory event  occurring 
simultaneously with the loss of a strong tumor-specific antigen. This is presently being 
investigated using other highly antigenic UV-induced fibrosarcomas. Interestingly, it 
has recently been demonstrated  (21)  that the sensitivity to NK cells may depend on 
the given stage of differentiation of the tumor cells and that only tumor cells expressing 
a  more immature phenotype may be effectively killed by natural killer cells. Tumor 
progression is associated with a  loss of differentiated cell function  and an increased 
malignant growth behavior. Therefore, an increase in sensitivity to natural killer cells 
may commonly develop in tumor cell populations undergoing tumor progression. 
Several other studies  (22-24)  have demonstrated  the development of immunore- 
sistant  variants with decreased expression of the tumor-specific antigen after immu- 
noselection  in  preimmunized  animals.  However,  these  investigators  did  not  test 
nonimmune animals, nor did they test for possible simultaneous changes in suscepti- 
bility to NK or other immune cells. If, after the loss of a strong tumor antigen, tumor 
cells commonly show an increased ability to induce and  be killed by natural  killer 
cells, then natural  killer cells may commonly play a  protective role against local or 
metastatic growth of tumors that escape tumor-specific immunity. For example, NK- 
1.2+Thy-l.2  -  cells have been shown (25)  to adoptively transfer resistance to artificial 
blood-borne metastases of the UV-induced  2237  progressor tumor. Nevertheless, we 
found that the progressor variants we have isolated grew faster in nude mice, which 
have significant  levels of natural killer activity, than in normal animals. Therefore, 
the  protective significance of NK cells may be restricted  at  least  in  this system to 
lower  numbers  of tumor  cells  or  to  tumor  cells  that  have  entered  the  vascular 
circulation. 
The differences in  growth behavior of the progressor tumors in  nude  vs. normal 
animals suggest  the  participation  of a  T  cell-mediated host  defense  mechanism  in 
normal animals. The fact that progressor tumors isolated from normal but not nude 
animals show  marked central  necrosis strongly suggests  that  the  normal  host  is  at 
least partially capable of destroying progressor tumor cells. We do not yet know which 
effector cells are attracted to the site of tumor growth, but it is conceivable that the 
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participates in the partial destruction of the tumor. In fact, other investigators  (26) 
have shown that hyperimmunization can generate cross-protection against antigeni- 
cally distinct  tumors, implying the existence of cross-reactive tumor transplantation 
antigens. It is questionable, however, whether cross-protection among different tumors 
can always be taken as evidence for the presence of shared tumor antigens. In elegant 
experiments, it has, for example, been shown (27,  28) that endotoxin can also induce 
complete tumor  regression  that  requires  T  cell-mediated  immunity.  This  does  not 
necessarily indicate that a common antigen is present on both the endotoxin and the 
tumors. 
In any case, the nonspecific tumor cytotoxicity we describe here does not appear to 
be  directed  solely  against  such  a  putative  cross-reacting  tumor  antigen  because 
nontumorigenic adult syngeneic fibroblasts were also killed. It has been suggested by 
Shustik and co-workers (29) that this type of promiscuous T cell-mediated cytotoxicity 
might  represent  a  polyclonal  differentiation  of effector lymphocytes. In  support  of 
this  conclusion,  we  have recently  found  that  the  cross-reactive cytolytic immunity 
generated in vitro after in vivo priming with progressor cells segregates to a significant 
degree into noncross-reactive clones when analyzed under limiting dilution conditions 
(J.  L.  Urban,  manuscript  in  preparation).  Thus,  injection  of normal  animals with 
progressor cells might induce a  nonspecific increase in the immune responsiveness to 
various antigens  in vivo and an increased susceptibility of the T  cells to polyclonal 
activation in vitro. 
Several groups of investigators  (30-32)  have used cultured  cell lines to isolate in 
vitro  clones  of tumor cells  that  were  either  tumorigenic  or  nontumorigenic  when 
injected  as "pure" clones into a  host.  Interestingly, it was shown recently  (32)  that 
such  progressor clones  derived  in  vitro  may not  be selected  for in  vivo.  This  was 
demonstrated  by the  fact that  injection  of low numbers of cells from the regressor 
clone, when mixed with even a  10-fold higher number of cells from the progressor 
clone, still resulted in the regressor (parental) phenotype. Thus, the biologic relevance 
of progressor clones derived in vitro in the emergence of variant tumor cell populations 
in the host during normal tumor progression remains uncertain. It is possible that the 
in vitro derived progressor clones did not  have a  selective growth advantage in the 
host  because  they  were  found  not  to  be  antigenically  different  from  the  regressor 
clones. In contrast, the variant progressor subpopulations selected for by the normal 
host and described in our study all lacked the original tumor-specific transplantation 
antigen. 
In conclusion, we studied the relative importance and hierarchy of different immune 
defense mechanisms that may enable a host to reject a syngeneic tumor without prior 
immunization. This was done by studying the fingerprints that the selective pressure 
of the  host  left  on  the  progressively  growing  variant  tumor  cell  population  that 
emerged  from the parental  regressor cell population.  Apparently,  selective pressure 
was exerted by tumor-specific cytotoxic T  cells or by other lymphocyte subclasses with 
the  same  specificity.  On  the  other  hand,  there  was  no  selection  by  NK  cells  or 
nonspecific  T  cells,  and  sensitivity  to  these  cells  was  not  sufficient  to  allow  the 
unimmunized host to reject the tumor. Thus, our study shows that the expression of 
the tumor-specific antigen is essential for the resistance of the unimmunized host to 
the 1591 regressor tumor. The present results are complementary to our earlier studies 
using anti-idiotypic  immune regulation  that  showed  the  critical  importance of the URBAN ET AL.  571 
presence of tumor-specific lymphocytes for this tumor resistance (9,  19). Nevertheless, 
these effector cells are probably not the only requirements for tumor resistance, and 
it is quite conceivable that the tumor must evade other effector mechanisms to grow 
progressively. For example, macrophages are known  to kill tumor cells in  vitro (2), 
and they are known to accumulate at the site of secondary tumor challenge in animals 
exhibiting concomitant tumor immunity  (33).  At present we do not know why the 
1591 tumor, when it changes to a progressor variant and loses the 1591-specific tumor 
antigen, becomes capable of inducing natural killer cells and cross-reacting cytolytic 
T  lymphocytes. This alteration may either represent a  detrimental  dysregulation of 
the  host's  defense  mechanism  against  the  tumor  or  an  induction  of a  valuable 
secondary  defense  mechanism  which,  if  boosted,  could  lead  to  tumor  rejection. 
Obviously,  the  therapeutic  approach  for  inducing  resistance  to  progressor  tumors 
would critically depend on which of these two mechanisms is operative. If, in fact, the 
progressor tumors cause a  dysregulation of the immune system, as shown in another 
tumor system  (34),  repair of such  dysregulation  may enable  the  host  to reject  the 
tumor by mounting a  response against  tumor antigens  that  remain or against  new 
ones that appear after the loss of the original tumor-specific antigen. 
Summary 
The ultraviolet radiation-induced fibrosarcoma 1591 generally is rejected by normal 
syngeneic mice and only rarely exhibits progressive growth. We isolated five of these 
rare progressor tumors from normal animals to determine the selective pressures that 
had been exerted upon the parental tumor by normal immunocompetent hosts. We 
found that the variant tumor cell lines could neither induce nor be killed by tumor- 
specific lymphocytes, suggesting that selection had been exerted against tumor cells 
expressing the tumor-specific antigen.  In contrast, no selection against natural killer 
cell activity or against nonspecific T  cell-mediated immunity seems to have occurred 
because progressor tumor cells were highly sensitive to these types ofeffector cells and 
in fact induced these effector cells more effectively than did the parental tumor. 
Nude mice were found to be as capable as normal mice in generating natural killer 
activity in response to a challenge with progressor tumor cells, but they were unable 
to mount a  nonspecific T  lymphocyte response. This may account for the fact that 
the  progressor tumors  grew  at  a  significantly  faster rate  in  nude  animals  than  in 
normal  mice.  Thus,  our study shows  that  in  this  tumor system nonspecific T  cell- 
mediated  immunity  may play a  role  in  retarding  tumor  growth,  but  the  absolute 
resistance of normal animals to progressive tumor growth critically depends upon the 
presence of T  cell-mediated tumor-specific immunity. Furthermore, neither NK cells 
nor nonspecific cytotoxic T  lymphocytes appear to play a  role in  immunoselection 
against this tumor in normal immunocompetent hosts. 
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